Health

Novavax says it is developing a COVID-19 vaccine targeting a new Omicron variant-National

Novavax Inc said on Friday that it will begin developing a version of the COVID-19 vaccine that targets variants detected in South Africa and will be ready for testing and production in the coming weeks.

The company’s COVID-19 shots contain the actual version of the viral peaplomer, which cannot cause illness but can induce the immune system. Vaccine developers said they started developing pesplomers specifically based on the known gene sequence B.1.1.529 of the mutant.

“The first work will take a few weeks,” a spokeswoman for the company said. The company’s stock closed almost 9% on Friday.

read more:

Canada cracks down on Omicron COVID-19 variant.Experts say it’s likely “already here”

The Novavax vaccine received its first emergency use authorization in Indonesia earlier this month, followed by the Philippines.

The story continues under the ad

The company said it plans to apply for US approval by the end of the year. We are also applying for approval not only in Canada but also in the European Medicines Agency.


Click to play video:



Tam describes a new “no indication” “Omicron” COVID-19 mutant that has ever existed in Canada.


Tam describes a new “no indication” “Omicron” COVID-19 mutant that has ever existed in Canada.

Other vaccine developers, including Germany’s BioN Tech SE and Johnson & Johnson, say they are testing the effectiveness of shots against a new variant named Omicron by the World Health Organization.

Inovio Pharmaceuticals Inc said it has begun testing the vaccine candidate INO-4800 and evaluated its efficacy against new variants. The company expects the test to take about two weeks.

read more:

Explainer: What is this new COVID-19 variant emerging in South Africa?

Inovio also said it was simultaneously designing new vaccine candidates specifically targeting Omicron.

The story continues under the ad

Kate Broderick, Senior Vice President of Research and Development at Inovio, said:

Earlier this month, Inovio resumed late-stage trials of the vaccine in the United States after a 14-month clinical hold.

(Report by Manojna Maddipatla and Mrinalika Roy in Bangalore, edited by Anil D’Silva)

See link ยป




Novavax says it is developing a COVID-19 vaccine targeting a new Omicron variant-National

Source link Novavax says it is developing a COVID-19 vaccine targeting a new Omicron variant-National

Related Articles

Back to top button